In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Repros Therapeutics, Inc.

http://www.reprosrx.com

Latest From Repros Therapeutics, Inc.

Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?

Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.

Tech Transfer Round-Up Coronavirus COVID-19

Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies

Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.

Regenerative Medicine Financing

Calithera Drops Development Of Lead Candidate Telaglenastat

Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.

Clinical Trials Cancer

Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing

I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Zonagen, Inc.
UsernamePublicRestriction

Register